Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx(TM) in Chronic Bronchitis at the European Respiratory Society
Favorable safety profile
RheOx treatment resulted in clinical improvement as measured by Quality of Life scores, with treatment effect maintained at 12-month follow-up
Improvement in airway biopsies and imaging
MENLO PARK, Calif., Sept. 17, 2018 -... Biopharmaceuticals Gala Therapeutics, RheOx, chronic bronchitis, Bronchial Rheoplasty
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news